Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers
LC Collins, A Martyniak, MJ Kandel… - The American journal …, 2009 - journals.lww.com
Background Over 80% of breast cancers in women with germline BRCA1 mutations are
estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-
negative (“triple negative”) and most of these have a basal-like phenotype by expression
profiling and immunophenotypic analysis. However, whether or not expression of
biomarkers characteristic of basal-like breast cancers helps to define a subset of women
with triple-negative breast cancers who are likely to harbor BRCA1 mutations is an …
estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-
negative (“triple negative”) and most of these have a basal-like phenotype by expression
profiling and immunophenotypic analysis. However, whether or not expression of
biomarkers characteristic of basal-like breast cancers helps to define a subset of women
with triple-negative breast cancers who are likely to harbor BRCA1 mutations is an …